Pulmonary inflammation promoted by type-2 dendritic cells is a feature of human and murine schistosomiasis.
Emma HoulderA H CostainI NambuyaS L BrownJan Pieter R KoopmanM C C LangenbergJ J JanseM A HoogerwerfA J L RidleyJ E Forde-ThomasS A P ColomboB M F WinkelA A GaldonKarl F HoffmannP C CookMeta RoestenbergH MpairweAndrew S MacDonaldPublished in: Nature communications (2023)
Schistosomiasis is a parasitic disease affecting over 200 million people in multiple organs, including the lungs. Despite this, there is little understanding of pulmonary immune responses during schistosomiasis. Here, we show type-2 dominated lung immune responses in both patent (egg producing) and pre-patent (larval lung migration) murine Schistosoma mansoni (S. mansoni) infection. Human pre-patent S. mansoni infection pulmonary (sputum) samples revealed a mixed type-1/type-2 inflammatory cytokine profile, whilst a case-control study showed no significant pulmonary cytokine changes in endemic patent infection. However, schistosomiasis induced expansion of pulmonary type-2 conventional dendritic cells (cDC2s) in human and murine hosts, at both infection stages. Further, cDC2s were required for type-2 pulmonary inflammation in murine pre-patent or patent infection. These data elevate our fundamental understanding of pulmonary immune responses during schistosomiasis, which may be important for future vaccine design, as well as for understanding links between schistosomiasis and other lung diseases.